High dilution in Leukopenia treatment in five dogs

Leukopenia is associated with the consumption of peripheral leukocytes, decreasedproduction due to endotoxemia and septicemia, medullary hypoplasia, nutritional diseases orautoimmune reactions. In a case report by Narita et al, Echinacea angustifolia demonstrated theeffectiveness of treatment of leukopenia in penguins. Aims:Report the evolution of homeopathictreatment in 5 dogs' patients between 3 and 5 years old, presenting leukopenia. Methodology:The homeopathic treatment was chosen, using Echinaceaangustifolia due to its immunostimulant andimmunomodulatory actions, which evolution was analyzed by blood tests. The exposedinformation is consented by the tutors. Results:The same protocol was made for all of the patients, including 4 globules of Echinacea angustifolia 6 cH orally, every 12 hours for 30 days. The first dog attended on 07/21/2021, presented 4.000 leukocytes, which increased to 6.800 on 08/17/2021. Thesecond patient attend on 12/07/2021 presented 4.700 leukocytes, increasing to 6.800 on 01/25/2022. The third patient attended on 08/24/2021 presented 5.400 leukocytes, which increased to 6.800 on 10/15/2021. The fourth patient presented 4.300 leukocytes on 01/13/2022, increasing to 5.500 on 02/11/2022. The fifth patient presented on12/12/2021 4.600 leukocytes, increasing to 8.400 on 02/03/2022. Therefore, the average of the first collection was 3.681 leukocytes and in the second there was an increase to 6.860 leukocytes (T-test, p= 0,0167). Conclusion:The use of the homeopathic medicine Echinacea angustifolia shows great results, being a viableoption for the treatment of leukopenia, without the side effects.

Insuficiencia medular / Bone marrow insufficiency

La insuficiencia medular es un síndrome hematológico; de pronóstico siempre reservado; que reconoce dos mecanismos etiopatogénicos: la aplasia medular y la mieloptisis. La primera es de naturaleza benigna y recuperable (50 por ciento) y la segunda maligna. Ambas se manifiestan clínicamente por una pancitopenia de la sangre periférica, la que se traduce por la asociación de un síndrome anémico normocítico y normocrómico arregenerativo, uno infeccioso febril y uno purpúrico. El diagnóstico clínico de insuficiencia medular es fácil, no así su tratamiento, especialmente en las mieloptisis.

Recombinant human erythropoietin and blood transfusion in low-birth weight preterm infants under restrictive transfusion guidelines

To compare the number and volume of red blood cell transfusions [RBCTs] in very low birth weight infants under restrictive red blood cell transfusion guidelines with and without erythropoietin administration. In a controlled clinical trial conducted at the neonatal intensive care unit of Alzahra Hospital, Isfahan, Iran, between April 2002 to April 2004, 60 premature infants with gestational age up to 34 weeks, birth weight up to 1500 g, and postnatal age between 8 and 14 days were included. The newborns were randomized into 2 groups: Group 1 received 3 doses of 400 IU/kg erythropoietin per week for 6 weeks, and Group 2 received no treatment aside from their conventional medications. The 2 groups did not differ significantly with respect to their mean gestational age, birth weight and hematocrit at the study entry. Fewer transfusions were administered to those receiving erythropoietin [26.7% versus 50%, p=0.03], but there was no statistically significant difference between groups with respect to volume of transfusion. Compared with the placebo group, the infants receiving erythropoietin had a higher mean hematocrit [34% +/- 4.3 versus 29% +/- 5.9, p<0.001] and absolute reticulocyte count [57 +/- 19 versus 10 +/- 4.8 x 106, p<0.001] at the end of the study. We found no significant difference in the incidence of thrombocytopenia and leukopenia between the 2 groups. We conclude that when the restrictive RBCT guidelines were followed, treatment with erythropoietin can be useful in reduction of the number of RBCTs

High dose epirubicin versus mitoxantrone in a seven-drug combination regimen for intermediate and high grade NHL: results of a randomized pilot study

The aim of the present pilot study was an attempt to improve the therapeutic outcome of this group of patients by increasing the dose of the most active drug i.e. anthracycline, through the use of high dose Epirubicin and compare it with the standard regimen in common use in the institution. Also, this work aimed at studying the safety of increasing the Epirubicin dose especially in terms of hematological [BM] and cardiotoxicity

Um caso clinico com esplenomegalia / A clinical case with splenomegaly

A autora apresenta o caso de um paciente com esplenomegalia consequente a leucopenia provocada por intoxicacao medicamentosa, com reversao do quadro apos tratamento homeopatico

Variación hematológica en bovinos jóvenes vacunados contra la leptopirosis / The hematologic changes after a leptopira monovalent vaccine in bovines 18 months were observed

Se observaron las variaciones hematológicas durante un mes, en bovinos < 18 meses inoculados con una vacuna monovalente de leptospira, se midieron títulos de anticuerpos (Ac), los cuales comenzaron a incrementarse a los siete días postvacunación (x: 1/15) y alcanzaron su máximo a los 21 días (x: 1/960). Al análisis estadístico se obtuvieron diferencias significativas (P< 0,05) en la proporción de monocitos (9,0 por ciento), aumento en la segunda semana; el número de eritrocitos (5,7x10 6/µ) Hc (26,1 por ciento) y la VESG (11,6 mm) incrementaron hacia la tercera semana, mientras que la resistencia de glóbulos rojos a solución salina hipotónica aumentó (0,45 por ciento de Nacl) y se observó una leucocitosis (9,6x 103/µ) hacia la cuarta semana. Las variaciones hematológicas observadas en los bovinos vacunados contra la leptopirosis fueron : en la primera semana se inició la producción de anticuerpos aglutinantes y alcanzan su máximo hacia la tercera y cuarta semana.A la segunda semana se nota una ligera leucopenia y hay una monocitosis. hacia la tercera semana hay un aumento en el número de eritrocitos, el hematócrito, así como también la velocidad de eritrosedimentación globular, y en la cuarta semana disminuyen los eritrocitos, el hematócrito y aumenta aún más la resistencia de los glóbulos rojos a solución salina hipotónica, así como también la velocidad de eritrosedimentación globular